Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5412-5421
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5412
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5412
Table 3 Associations between gut failure markers and disease or laboratory characteristics in patients with primary sclerosing cholangitis at enrolment
Anti-F-actin IgA | Anti-F-actin IgG | Anti-gliadin IgA | Anti-gliadin IgG | |||||||||
Negative (n = 48) | Positive (n = 19) | P value | Negative (n = 50) | Positive (n = 17) | P value | Negative (n = 61) | Positive (n = 6) | P value | Negative (n = 53) | Positive (n = 14) | P value | |
Male gender, n (%) | 35 (72.9) | 13 (68.4) | 0.713 | 38 (76.0) | 10 (58.8) | 0.175 | 44 (72.1) | 4 (66.7) | 0.777 | 37 (69.8) | 11 (78.6) | 0.518 |
Presence of cirrhosis, n (%) | 8 (16.7) | 5 (26.3) | 0.368 | 9 (18.0) | 4 (23.5) | 0.618 | 11 (18) | 2 (33.3) | 0.366 | 10 (18.9) | 3 (21.4) | 0.829 |
Presence of IBD, n (%) | 36 (75) | 15 (78.9) | 0.733 | 40 (80.0) | 11 (64.7) | 0.201 | 47 (77) | 4 (66.7) | 0.569 | 40 (75.5) | 11 (78.6) | 0.809 |
Median, IQR | ||||||||||||
Age at diagnosis (yr) | 23 (17-33) | 26 (18-37) | 0.713 | 25 (17-37) | 20 (11-31) | 0.220 | 23 (17-35) | 23 (18-29) | 0.925 | 23 (17-37) | 22 (17-29) | 0.502 |
Disease duration (yr) | 6 (3-8) | 7 (2-12) | 0.240 | 6 (4-10) | 6 (1-9) | 0.219 | 6 (3-9) | 9 (1-12) | 0.760 | 6 (3-8) | 6 (2-17) | 0.506 |
Albumin (g/L) | 44 (42-46) | 39 (38-47) | 0.020 | 44 (40-46) | 43 (39-47) | 0.442 | 44 (40-47) | 39 (39-42) | 0.210 | 44 (40-46) | 43 (39-47) | 0.726 |
Bilirubin (μmol/L) | 15 (11-20) | 14 (11-37) | 0.704 | 15 (11-20) | 13 (10-22) | 0.705 | 14 (10-22) | 17 (16-21) | 0.216 | 15 (11-23) | 17 (12-20) | 0.813 |
AST (U/L) | 35 (25-56) | 55 (37-94) | 0.006 | 36 (27-56) | 44 (34-85) | 0.182 | 39 (28-61) | 41 (34-48) | 0.861 | 42 (28-61) | 35 (25-55) | 0.524 |
ALT (U/L) | 46 (21-92) | 65 (45-165) | 0.030 | 50 (25-97) | 55 (32-165) | 0.532 | 52 (25-100) | 44 (37-52) | 0.294 | 54 (32-111) | 42 (24-65) | 0.188 |
GGT (U/L) | 142 (45-269) | 193 (112-478) | 0.041 | 153 (63-305) | 153 (60-420) | 0.748 | 154 (60-310) | 140 (93-305) | 0.943 | 160 (54-310) | 126 (88-305) | 0.895 |
ALP (U/L) | 406 (253-643) | 1198 (595-1766) | < 0.001 | 469 (268-734) | 715 (507-1496) | 0.040 | 524 (312-784) | 1204 (307-1299) | 0.336 | 507 (326-746) | 652 (268-1204) | 0.394 |
PLT (G/L) | 238 (181-292) | 315 (162-494) | 0.212 | 235 (175-274) | 320 (162-466) | 0.066 | 248 (165-316) | 274 (232-494) | 0.292 | 253 (165-316) | 241 (187-356) | 0.751 |
Mayo risk score | -0.834 (-1.378 to -0.131) | 0.021 (-0.554-1.248) | 0.016 | -0.62 (-1.142-0.102) | -0.226 (-1.578-0.292) | 0.623 | -0.595 (-1.194-0.102) | 0.021 (-0.843-1.327) | 0.429 | -0.579 (-1.102-0.174) | -0.651 (-1.194-0.021) | 0.762 |
- Citation: Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. World J Gastroenterol 2017; 23(29): 5412-5421
- URL: https://www.wjgnet.com/1007-9327/full/v23/i29/5412.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i29.5412